Key result
Optimal multidisciplinary regimens fail to prevent death in ~50% of pediatric extremity rhabdomyosarcoma cases.
Why the study?
Extremity rhabdomyosarcoma in children and adolescents is a complex disease with high mortality despite current treatments, requiring coordinated multidisciplinary management and exploration of new therapeutic approaches.
Extremity rhabdomyosarcoma in children requires coordinated multidisciplinary care, with emerging local control methods like regional arterial perfusion and intraoperative brachytherapy being explored.
Answers are grounded in this paper and cite their sources.
Emphasizes persistent high mortality from distant failure in pediatric extremity RMS; leaves open optimal systemic strategies for prospective trials.
Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and adolescence with 20% of the primary tumors anatomically located on extremities. It is a complicated entity that requires careful planning and coordination between the surgical oncologist and other members of the therapeutic team for successful treatment. Even with the most effective regimens more than 50% of patients will die from progressive, usually distant disease. Further progress may require new therapeutic agents or techniques. The surgical oncologist is a necessary and often prominent member of the team. Elements of the biological behavior, histopathology, clinical staging, and treatment of extremity rhabdomyosarcomas occurring in children are discussed. In particular, the importance of the alveolar subtype in determination of prognostic risk as well as new findings regarding the molecular biologic determinants of phenotypic behavior are mentioned. Finally, innovative methods of local control like regional arterial perfusion and rapid intraoperative brachytherapy are addressed.
No takes yet. Share an insight, caveat, or question.
Michael P. LaQuaglia (1993) conducted a review in Extremity rhabdomyosarcoma. Extremity rhabdomyosarcoma in childhood and adolescence is a complex disease where, despite the most effective regimens, more than 50% of patients die from progressive, usually distant disease.
Synapse has enriched 10 related papers. Consider them for comparative context: